Patents Issued in August 14, 2018
  • Patent number: 10047097
    Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: August 14, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
  • Patent number: 10047098
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminopyrimidinone compounds, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein RN, R1, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 14, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xing Dai, Jared N. Cumming, Hong Liu, Jack D. Scott
  • Patent number: 10047099
    Abstract: The present invention provides a method for producing anhydrosugar alcohol, including: feeding sugar alcohol into a reactor and performing a dehydration reaction of the fed sugar alcohol to produce anhydrosugar alcohol; and supplying steam to the reactor to evaporate the produced anhydrosugar alcohol. According to the present invention, anhydrosugar alcohol can be produced in a high yield by increasing the specific surface area of reaction mother liquor and reducing the partial pressure of the product.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: August 14, 2018
    Assignee: SK Innovation Co., Ltd.
    Inventors: Sung Real Son, Suk Joon Hong, In Hyoup Song, Yoon Jae Yim
  • Patent number: 10047100
    Abstract: Compounds of formula III: and salts thereof are disclosed. Also disclosed are methods for preparing compounds of formula III, intermediates useful for preparing compounds of formula III and methods for preparing compounds and materials from compounds of formula III.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: August 14, 2018
    Inventors: Thomas R. Hoye, Ashok Pehere, Shu Xu
  • Patent number: 10047101
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: August 14, 2018
    Assignee: Janssen Pharmaceautica NV
    Inventors: Wendy Eccles, Anne E. Fitzgerald, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Jing Liu, Neelakandha S. Mani, Kelly J. McClure, Steven P. Meduna, Mark D. Rosen
  • Patent number: 10047102
    Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: August 14, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
  • Patent number: 10047103
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: August 14, 2018
    Assignees: Bristol-Myers Squibb Company, Universite de Montreal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Patent number: 10047104
    Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: August 14, 2018
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
  • Patent number: 10047105
    Abstract: Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 14, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Creighton, Leslie William Tari, Zhiyong Chen, Mark Hilgers, Thanh To Lam, Xiaoming Li, Michael Trzoss, Junhu Zhang, John Finn, Daniel Bensen
  • Patent number: 10047106
    Abstract: The present invention relates to luminescent lanthanide complexes including a chelating agent, formed with a macrocycle or a set of ligands, complexing a lanthanide ion Ln3+, wherein the chelating agent is substituted with at least two groups. The invention is most particularly applied to lanthanide complexes, the chelating agent of which is formed the with three ligands integrating a 2,6 pyridine-di(carboxylic acid) or is formed with a macrocycle having a 1,4,7 triazacyclononane structure.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: August 14, 2018
    Assignees: ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON I, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Olivier Maury, Chantal Andraud, Virginie Placide, Delphine Pitrat
  • Patent number: 10047107
    Abstract: The invention relates to amino nitrile compounds. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: August 14, 2018
    Assignee: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
    Inventors: Bhaskar C. Das, Nikhil V. Dhurandhar
  • Patent number: 10047108
    Abstract: A process for the hydrosilylation of an unsaturated compound comprising reacting (a) a silyl hydride with (b) an unsaturated compound in the presence of (c) a platinum based hydrosilylation catalyst comprising a platinum-diene complex with chelating anions. The use of the present catalysts in the process provides silylated products in good yields and allows for using lower platinum loadings than conventional catalysts, reduced cycle times, and may reduce yellowing in the product.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: August 14, 2018
    Assignee: MOMENTIVE PERFORMANCE MATERIALS INC.
    Inventors: Julie L. Boyer, Aroop K. Roy, David Jenkins, Indraneel Kundu
  • Patent number: 10047109
    Abstract: The present disclosure relates to a reactive porogen using cyclic organic polyol and an ultra low dielectric film prepared using the same, and more particularly, to novel cyclic organic polyol as a cyclic organic polyol compound which can be completely pyrolyzed at a temperature of 500° C. or less, does not leave carbon residue during a heat treatment if an end hydroxyl group of the cyclic organic compound is substituted by a functional group of alkylalkoxysilane and then used as a reactive porogen, and is involved in a sol-gel reaction of organic silicate and suppresses phase separation and thus forms pores having a uniform size and has excellent mechanical properties as compared with a porosity, a reactive porogen using the ash-free cyclic organic polyol, and an ultra low dielectric film prepared using the same.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: August 14, 2018
    Assignee: Sogang University Research Foundation
    Inventors: Hee-Woo Rhee, Sung-Min Cho
  • Patent number: 10047110
    Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-? using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. A nucleic acid molecule can have a) a polynucleotide sense strand and a polynucleotide antisense strand; b) each strand of the molecule being from 15 to 30 nucleotides in length; c) a contiguous region of from 15 to 30 nucleotides of the antisense strand being complementary to a sequence of an mRNA encoding GST-?; and d) at least a portion of the sense strand can be complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: August 14, 2018
    Assignee: Nitto Denko Corporation
    Inventors: Kenjirou Minomi, Hirokazu Takahashi, Erika Terada, Jens Harborth, Jun Zhang, Mohammad Ahmadian, Wenbin Ying
  • Patent number: 10047111
    Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-? using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2?-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: August 14, 2018
    Assignee: Nitto Denko Corporation
    Inventors: Kenjirou Minomi, Hirokazu Takahashi, Erika Terada, Jens Harborth, Jun Zhang, Mohammad Ahmadian, Wenbin Ying
  • Patent number: 10047112
    Abstract: Provided herein are a series of fluorescently labeled phosphonate and phosphate compounds such as can be used for affinity probes to detect certain enzymes including lipases. Also provided are methods of making and using such compounds.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: August 14, 2018
    Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Christopher D. Spilling, Benjamin P. Martin, Stephane Canaan, Jean-Francois Cavalier
  • Patent number: 10047113
    Abstract: The invention relates to nucleic acids encoding a feruloyl-CoA:monolignol transferase and the feruloyl-CoA:monolignol transferase enzyme that enables incorporation of monolignol ferulates, for example, including p-coumaryl ferulate, coniferyl ferulate, and sinapyl ferulate, into the lignin of plants.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 14, 2018
    Assignees: Board of Trustees of Michigan State University, The University of British Columbia, Wisconsin Alumni Research Foundation
    Inventors: Curtis Wilkerson, John Ralph, Saunia Withers, Shawn D. Mansfield
  • Patent number: 10047114
    Abstract: The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 14, 2018
    Assignee: Spring Bank Pharmaceuticals, Inc.
    Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
  • Patent number: 10047115
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: August 14, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Keith Biggadike, Aurelie Cecile Champigny, Diane Mary Coe, Deborah Needham, Daniel Terence Tape
  • Patent number: 10047116
    Abstract: The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: August 14, 2018
    Assignee: MX Adjuvac AB
    Inventors: Bror Morein, Saideh Berenjian, Kafei Hu
  • Patent number: 10047117
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 14, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Patent number: 10047118
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 14, 2018
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Jie Chen, Yan Chen, Nicholas A. Meanwell, Alicia Regueiro-Ren, Ny Sin, Sing-Yuen Sit
  • Patent number: 10047119
    Abstract: Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPB), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: August 14, 2018
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Nicholas David Peter Cosford, Mitchell Dennis Vamos
  • Patent number: 10047120
    Abstract: The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralizing a tooth lesion such as a subsurface caries lesion.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: August 14, 2018
    Assignee: Credentis AG
    Inventors: Michael Hug, Dominikus Amadeus Lysek
  • Patent number: 10047121
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to ??(20-42) globulomer or any ?? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: August 14, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Chung-Ming Hsieh
  • Patent number: 10047122
    Abstract: The invention provides novel compounds that may serve as anticancer therapeutics. The compounds of the invention bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds of the invention are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected phophoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives of the invention have achieved both good efficacy and an enhanced bioavailability. The invention also provides methods of use, compositions, and kits thereof. Further, the invention provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 14, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Wenjian Qian, Jung Eun Park, Christopher C. Lai, James A. Kelley, Kyung S. Lee, Terrence R. Burke, Jr.
  • Patent number: 10047123
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 14, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Patent number: 10047124
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 14, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Patent number: 10047125
    Abstract: A peptide having activity to improve skin condition is described. The peptide exhibits a very excellent effect in improving skin condition by inhibiting MMP2 activity. A composition containing the peptide exhibits excellent biological activities, such as inhibiting collagen decomposition and melanosome migration, and thus can be used in wrinkle reduction, skin regeneration, skin elasticity improvement, anti-skin aging, wound regeneration, acne reduction, skin regeneration or skin whitening. The composition containing the peptide can be used as a pharmaceutical composition for preventing or treating MMP activity-related diseases and inflammation diseases.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: August 14, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10047126
    Abstract: The present invention relates to antimicrobial compounds and their uses, and in particular to peptide antibiotics which may be used in the treatment of bacterial infections such as Gram-negative bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 14, 2018
    Assignee: Monash University
    Inventors: Jian Li, Roger Nation, Tony Velkov, Philip Thompson, Kade D. Roberts
  • Patent number: 10047127
    Abstract: Provided is a supramolecular polypeptide comprising alternating repeats of crystallite-forming subsequences and amorphous subsequences. The crystallite-forming subsequences form crystallites comprising stacks of one or more ?-sheets and the amorphous subsequences form a network of hydrogen bonds. The supramolecular polypeptides are capable of exhibiting self-healing behavior.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: August 14, 2018
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Melik Demirel, Benjamin Allen, Huihun Jung
  • Patent number: 10047128
    Abstract: The present invention is a peptide lock that comprises at least one peptide that is genetically encoded into the Adeno-associated virus (AAV) capsid that block biologically active domains on the virus capsid surface. The peptide lock, can be processed by biological enzymes to restore biological behavior of the capsid-displayed domains, thus ‘decoding the lock’ or opening the lock. A method of forming the peptide lock comprises providing at least one peptide, providing an Adeno-associated virus capsid and genetically inserting the at least one peptide into the Adeno-associated virus capsid to block the biologically active domains on the virus capsid surface.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 14, 2018
    Assignee: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Justin Judd, Junghae Suh, Jonathan Silberg
  • Patent number: 10047129
    Abstract: Provided herein are alpha hemolysin polypeptides comprising modified amino acid sequences that can reduce the rate of translocation of a polymer. Also provided herein are apparatuses and devices comprising modified hemolysin polypeptides. Also provided herein are methods of using modified alpha hemolysin proteins for use in characterizing and/or sequencing a polymer or for use as molecular sensors.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: August 14, 2018
    Assignee: ELECTRONIC BIOSCIENCES, INC.
    Inventors: Geoffrey A. Barrall, Eric N. Ervin, Prithwish Pal
  • Patent number: 10047130
    Abstract: The present disclosure provides compositions and methods used for optogenetics, wherein the composition comprises an optogenetic device and a retinoid processing enzyme.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: August 14, 2018
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Joseph C. Corbo, Jennifer Enright, Matthew Toomey
  • Patent number: 10047131
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 14, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10047132
    Abstract: The present disclosure provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 14, 2018
    Inventor: Peter C. Dowling
  • Patent number: 10047133
    Abstract: The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: August 14, 2018
    Assignee: Antagonis Biotherapeutics GmbH
    Inventor: Andreas Kungl
  • Patent number: 10047134
    Abstract: The present disclosure relates to a comprehensive model for expression of recombinant peptides by Pichia pastoris. The model uses an easily controllable variable called ‘critical nutrient ratio’ for obtaining a right balance between product synthesis and it's degradation during the fermentation process. The extra cellular concentration of precursor could be increased by about 10 folds and the degradation constants could be reduced by about 10-20 folds for intracellular and extracellular cases respectively by controlling critical nutrient ratio and addition of soya flour hydrolysate and EDTA.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 14, 2018
    Assignee: Biocon Limited
    Inventors: Sanjay Tiwari, Gourav Awasthi, Gokul Jothiraman, Arun Chandavarkar
  • Patent number: 10047135
    Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: August 14, 2018
    Assignee: STC.UNM
    Inventor: Yubin Miao
  • Patent number: 10047136
    Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: August 14, 2018
    Assignee: Corning Incorporated
    Inventors: Na Li, Jie Wang, Christopher J. Patten
  • Patent number: 10047137
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: August 14, 2018
    Assignee: VERSITECH LIMITED
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
  • Patent number: 10047138
    Abstract: Described herein are novel fusion proteins and nucleic acids encoding these fusion proteins. T cells into which such nucleic acids have been introduced are also contemplated. These T cells can express the fusion proteins on their cell surface. In various embodiments, these T cells can be used in assays to detect costimulatory ligands, inhibitors of costimulatory ligands, or inhibitors that can neutralize an inhibitor of a costimulatory ligand. Such assay methods are also described herein.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 14, 2018
    Assignee: AMGEN INC.
    Inventor: Christian Vettermann
  • Patent number: 10047139
    Abstract: Provided is an Fc fusion high affinity IgE receptor ?-chain having excellent stability at low pH. An Fc fusion protein comprising: (i) a high affinity IgE receptor ?-chain; and (ii) an Fc region of IgG1, wherein a linker fragment region between the (i) and the (ii) is the amino acid sequence shown in SEQ ID NO: 2.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 14, 2018
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Takashi Sakamoto, Yoichi Inada, Kazumasa Yokoyama
  • Patent number: 10047140
    Abstract: TRPV4 activation increases vascular permeability and can be triggered by both chemical and mechanical cues. This activation of TRPV4 can contribute to a number of pathological conditions, e.g., edema, inflammation, hypertension, and/or hyperalgesia. Described herein are methods and compositions relating to inhibition of mechanically-induced TRPV4 activation, e.g., for the treatment of pulmonary edema, edema, inflammation, hypertension, and/or hyperalgesia.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: August 14, 2018
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Donald E. Ingber, Mariko Kobayashi
  • Patent number: 10047141
    Abstract: Perfusion media are disclosed providing excellent cell density, titer and product quality for production of a therapeutic protein in a perfusion process.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: August 14, 2018
    Assignee: Coherus Biosciences, Inc.
    Inventors: Ela Puchacz, James Russell Grove
  • Patent number: 10047142
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 14, 2018
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Patent number: 10047144
    Abstract: The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and/or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: August 14, 2018
    Assignee: NovImmune SA
    Inventors: Greg Elson, Nicolas Fouque, Jean-Francois Depoisier, Nicolas Fischer, Giovanni Magistrelli
  • Patent number: 10047145
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: August 14, 2018
    Assignee: Humabs Biomed SA
    Inventor: Davide Corti
  • Patent number: 10047146
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 14, 2018
    Assignee: The Rockefeller University
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 10047147
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: August 14, 2018
    Assignee: The United States of American, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose